KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Non Operating Investment Income: 2019-2025

Historic Non Operating Investment Income for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $4.0 million.

  • Royalty Pharma's Non Operating Investment Income rose 33.33% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.0 million, marking a year-over-year decrease of 1226.76%. This contributed to the annual value of -$6.0 million for FY2024, which is 162.01% down from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Non Operating Investment Income is $4.0 million, which was up 300.00% from -$2.0 million recorded in Q2 2025.
  • Royalty Pharma's Non Operating Investment Income's 5-year high stood at $71.8 million during Q2 2022, with a 5-year trough of -$17.0 million in Q3 2021.
  • In the last 3 years, Royalty Pharma's Non Operating Investment Income had a median value of -$850,000 in 2023 and averaged -$911,250.
  • Over the last 5 years, Royalty Pharma's Non Operating Investment Income had its largest YoY gain of 3,861.39% in 2022, and its largest YoY loss of 920.83% in 2022.
  • Over the past 5 years, Royalty Pharma's Non Operating Investment Income (Quarterly) stood at -$96,000 in 2021, then slumped by 920.83% to -$980,000 in 2022, then tumbled by 133.66% to -$8.7 million in 2023, then soared by 134.56% to -$9.0 million in 2024, then soared by 33.33% to $4.0 million in 2025.
  • Its Non Operating Investment Income stands at $4.0 million for Q3 2025, versus -$2.0 million for Q2 2025 and -$1.0 million for Q1 2025.